Back to Journals » Drug Design, Development and Therapy » Volume 15

An Overview of Bimekizumab for the Treatment of Psoriatic Arthritis: The Evidence so Far

Authors G Oliveira D, Faria R, Torres T

Received 21 January 2021

Accepted for publication 25 February 2021

Published 9 March 2021 Volume 2021:15 Pages 1045—1053

DOI https://doi.org/10.2147/DDDT.S267405

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 4

Editor who approved publication: Dr Georgios D. Panos


Daniel G Oliveira,1 Raquel Faria,2,3 Tiago Torres3,4

1Department of Internal Medicine, Centro Hospitalar e Universitário do Porto, Porto, Portugal; 2Clinical Immunology Unit (UIC), Centro Hospitalar e Universitário do Porto, Porto, Portugal; 3Unit for Multidisciplinary Research in Biomedicine, Instituto de Ciências Biomédicas Abel Salazar – University of Porto, Porto, Portugal; 4Department of Dermatology, Centro Hospitalar e Universitário do Porto, Porto, Portugal

Correspondence: Tiago Torres
Department of Dermatology, Centro Hospitalar Universitário do Porto, Rua D. Manuel II, s/n, ex-CICAP, Porto, 4099-001, Portugal
Email [email protected]

Abstract: Psoriatic arthritis is a complex and heterogeneous disease with potential significant disability and impaired quality of life. Although in the last decades new treatment options have led to a better management of this disease, there are still significant unmet therapeutic needs. Dual inhibitor antibodies target two different cytokines simultaneously, potentially offering a better disease control. In psoriatic arthritis, there is evidence for a pathogenic role not only of IL-17A but also the structurally homologous IL-17F. It is postulated that differential expression of both in several targets of PsA could account for disparities in clinical response to IL-17A inhibition alone (such as with secukinumab or ixekizumab). Here we review the evidence so far for the use in psoriatic arthritis of bimekizumab, the first humanized monoclonal IgG1 antibody that selectively neutralizes both IL-17A and IL-17F. A Phase 2b trial reports better outcomes over both placebo and IL-17A inhibition alone. Very recently encouraging results from open-label extensions with regards to both safety and maintenance of response were presented. Phase III trials are ongoing with the first results awaited in 2021.

Keywords: psoriatic arthritis, psoriasis, bimekizumab, interleukin-17A, interleukin-17F, biologic therapy

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]